VolitionRx Reports Q3 2026 Financial Results and Operations Update

VolitionRx Limited, a multinational epigenetics company trading on NYSE American under the ticker VNRX, released its third-quarter 2026 financial results and an accompanying business update on Wednesday, Nov. 12, according to a company announcement issued from Henderson, Nevada.

The Henderson-based firm scheduled a conference call for Friday, Nov. 13, at 8:30 a.m. Eastern Time to walk investors and analysts through the financial and operational details of the quarter. Such calls typically allow management to address questions about revenue trends, research progress, and near-term strategic priorities.

Read more Windward Bio Debuts on Nasdaq, Shares Surge 68% on IPO Day →

VolitionRx describes itself as a multinational epigenetics company, a field focused on understanding how gene expression changes without altering underlying DNA sequences. Epigenetics-based diagnostics have drawn growing investor attention as researchers explore applications in early disease detection and personalized medicine, areas where the company has indicated it is active.

The quarterly disclosure follows standard reporting obligations for companies listed on NYSE American, the exchange formerly known as AMEX that tends to list smaller-capitalization firms. Investors seeking granular figures on revenue, operating expenses, and cash position were directed to the full results and the upcoming call.

Continue reading at All Financial Services & Investing.